TY - JOUR
T1 - Safety and Feasibility of a Sheath Cryoprobe for Bronchoscopic Transbronchial Biopsy
T2 - The FROSTBITE Trial
AU - Thiboutot, Jeffrey
AU - Illei, Peter B.
AU - Maldonado, Fabien
AU - Kapp, Christopher M.
AU - Demaio, Andrew
AU - Lee, Hans J.
AU - Feller-Kopman, David
AU - Lentz, Robert J.
AU - Sathyanarayan, Priya
AU - Rahman, Najib M.
AU - Silvestri, Gerard A.
AU - Yarmus, Lonny
N1 - Funding Information:
This investigator-initiated trial was funded by ERBE Elektromedizin, GmbH.
Funding Information:
Jeffrey Thiboutot, MD, Peter B. Illei, MD, Christopher M. Kapp, MD, Andrew DeMaio, MD, Hans J. Lee, MD, David Feller-Kopman, MD, Robert J. Lentz, MD, Priya Sathyanarayan, BS, Najib M. Rahman, BMBCh, DPhil, and Gerard A. Silvestri, MD have no conflicts of interest. Fabien Maldonado, MD and Lonny Yarmus, DO MBA have received grant support from ERBE. Lonny Yarmus, DO, MBA has performed consulting with Olympus Corp, Intuitive Surgical, Johnson and Johnson, and Boston Scientific.
Publisher Copyright:
© 2022 S. Karger AG. All rights reserved.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Background: Bronchoscopic lung biopsy is typically performed using transbronchial forceps. However, this method is limited by small sample size and presence of crush artifact. Cryobiopsy offers the potential to overcome these limitations with larger artifact-free samples but has not been widely adopted due to concerns over increased rates of bleeding and pneumothorax. A new, smaller 1.1-mm cryoprobe has been developed that operates in a similar fashion to forceps, though the safety profile of this cryoprobe has not yet been prospectively studied. Objective: The aim of this study was to investigate the safety of transbronchial biopsy using a novel 1.1-mm cryoprobe. Methods: This prospective, single-Arm study enrolled patients referred for transbronchial biopsy. All procedures were performed using the 1.1-mm cryoprobe with oversheath. The primary outcome was the composite of significant complications related to the cryobiopsy procedure (bleeding Grade ≥3, pneumothorax Grade ≥2, and respiratory failure). Bleeding and pneumothorax were graded according to previously published scales. Results: Fifty participants from two academic medical centers underwent transbronchial cryobiopsy. Indications for biopsy included evaluation of lung transplant allograft (50%), diffuse lung disease (44%), and pulmonary parenchymal lesion (6%). There were two pneumothoraces (4%), neither of which required aspiration or chest tube placement. There were no Grade 3 or 4 bleeding events. Mild bleeding (Grade ≤2) was observed in 25 cases (50%). No complications occurred that met the a priori primary outcome of bleeding Grade ≥3, pneumothorax Grade ≥2, and respiratory failure. Conclusions: Transbronchial cryobiopsy using a 1.1-mm cryoprobe is feasible with an acceptable safety profile.
AB - Background: Bronchoscopic lung biopsy is typically performed using transbronchial forceps. However, this method is limited by small sample size and presence of crush artifact. Cryobiopsy offers the potential to overcome these limitations with larger artifact-free samples but has not been widely adopted due to concerns over increased rates of bleeding and pneumothorax. A new, smaller 1.1-mm cryoprobe has been developed that operates in a similar fashion to forceps, though the safety profile of this cryoprobe has not yet been prospectively studied. Objective: The aim of this study was to investigate the safety of transbronchial biopsy using a novel 1.1-mm cryoprobe. Methods: This prospective, single-Arm study enrolled patients referred for transbronchial biopsy. All procedures were performed using the 1.1-mm cryoprobe with oversheath. The primary outcome was the composite of significant complications related to the cryobiopsy procedure (bleeding Grade ≥3, pneumothorax Grade ≥2, and respiratory failure). Bleeding and pneumothorax were graded according to previously published scales. Results: Fifty participants from two academic medical centers underwent transbronchial cryobiopsy. Indications for biopsy included evaluation of lung transplant allograft (50%), diffuse lung disease (44%), and pulmonary parenchymal lesion (6%). There were two pneumothoraces (4%), neither of which required aspiration or chest tube placement. There were no Grade 3 or 4 bleeding events. Mild bleeding (Grade ≤2) was observed in 25 cases (50%). No complications occurred that met the a priori primary outcome of bleeding Grade ≥3, pneumothorax Grade ≥2, and respiratory failure. Conclusions: Transbronchial cryobiopsy using a 1.1-mm cryoprobe is feasible with an acceptable safety profile.
UR - http://www.scopus.com/inward/record.url?scp=85139153957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139153957&partnerID=8YFLogxK
U2 - 10.1159/000526876
DO - 10.1159/000526876
M3 - Article
C2 - 36265451
AN - SCOPUS:85139153957
SN - 0025-7931
VL - 101
SP - 1131
EP - 1138
JO - Schweizerische Zeitschrift für Tuberkulose. Revue suisse de la
JF - Schweizerische Zeitschrift für Tuberkulose. Revue suisse de la
IS - 12
ER -